AGA Family of Websites: Gastro.org
AGA Journals
AGA Journals
AGA University
AGA University
AGA University
AGA Research Foundation
AGA University
AGA Community
AGA University
AGA Job Board
September 18, 2019

Pharmacology for IBD made easy by new, on demand course

Complete online training and receive free CE and pharmacology credits.

Share on facebook
Share on twitter
Share on linkedin
Share on email

To help clinicians understand the foundation of pharmacology and new therapies as they pertain to inflammatory bowel disease (IBD), AGA has released a free, on-demand course through AGA University. 

Designed by clinical nurse practitioners and presented in a case-based format, Advanced Practice Provider Pharmacology: IBD covers the three most prevalent pharmacological treatments for IBD: 5-aminosalicylic acid (5-ASA) drugs, biologics and immunomodulators.

Why participate?
  • Complimentary access. This program is available to all AGA members and nonmembers through AGA University. Easily accessible from home or the office, participants can plan a lunch-and-learn with peers or learn at their own pace.
  • Learn from esteemed colleagues. This two-hour course provides a comprehensive overview for GI professionals of all levels. Expert faculty include Kimberly Kearns, MS, APRN, ANP-BC (Chair), Erin Darguzas, MSN, APN, and Shawna Sullivan, MSN, APRN, ACNP-BC.
  • Earn continuing education credit. After competition of this course, participants will be eligible to receive 2 AMA PRA Category 1 Credits™ or 2 pharmacology credit hours through AANP.

Gain the knowledge you need to remain a leader in the field — participate in Advanced Practice Provider Pharmacology: IBD today!

This program was supported by independent educational grants from Gilead Sciences, Inc. and Takeda Pharmaceuticals U.S.A., Inc.

Discussion Icon

Discuss this news

Share this article in the AGA Community, your member-only platform for sharing your thoughts and ideas with your colleagues.

Not a member? Join AGA.

By using this site, you agree to our updated Privacy Policy.